Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H17N2O.C2H3O2 |
Molecular Weight | 336.3844 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC([O-])=O.CC1=C2C=C[N+](C)=CC2=C(C)C3=C1NC4=C3C=C(O)C=C4
InChI
InChIKey=BOMZMNZEXMAQQW-UHFFFAOYSA-N
InChI=1S/C18H16N2O.C2H4O2/c1-10-15-9-20(3)7-6-13(15)11(2)18-17(10)14-8-12(21)4-5-16(14)19-18;1-2(3)4/h4-9,21H,1-3H3;1H3,(H,3,4)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/7003658
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7003658
Elliptinium is an antineoplastic agent, which was used in the treatment of metastatic breast cancer in France under the name Celiptium. The drug is known to intercalate into DNA and inhibit topoisomerase II. Several studies have demonstrated that this molecule can be oxidized, yielding a reactive electrophilic form, which is able to bind covalently to a nucleophilic biological molecule.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7003658 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CELIPTIUM Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Virostatic in vivo effect of elliptinium on Friend's retrovirus (a model for HIV infection). | 1990 |
|
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model. | 1991 Nov-Dec |
|
Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model. | 1993 Mar |
|
Inhibitors of human immunodeficiency virus integrase. | 1993 Mar 15 |
|
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation. | 2002 Jan |
|
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. | 2005 Nov 28 |
|
Anticancer drugs from marine flora: an overview. | 2010 |
|
Immunotargeting of collagenase on thrombus. | 2010 Nov 16 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8484977
In a clinical study, elliptinium (acetate salt) was given at a dose of 80 mg/m2 daily for 3 consecutive days every 21 days.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1968
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
||
|
NCI_THESAURUS |
C582
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4783
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
C1367
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
261-216-0
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
C027767
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
DTXSID10207068
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL16699
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
264137
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
H9B41234P4
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
100000080728
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
m4874
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
58337-35-2
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
SUB06489MIG
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY | |||
|
42722
Created by
admin on Fri Dec 15 15:16:47 GMT 2023 , Edited by admin on Fri Dec 15 15:16:47 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD